Cluster Headache Syndrome Market Key Opportunities and Forecast up to 2024

The global cluster headache syndrome market is foreseen to be advantaged by the advent of new medical equipment and drugs for treatment. For instance, neuroscience and technology company electroCore has publicized the commercial launch of a non-invasive vagus nerve stimulator gammaCore that could treat acute pain experienced by adult patients with episodic cluster headache in the U.S. It is supposedly the first hand-held, non-invasive medical equipment applied at the neck that activates the vagus nerve to reduce pain by sending patented and gentle electrical stimulation through the skin.

Furthermore, according to a latest research, chemical compounds, viz. cannabidiol (CBD) and tetrahydrocannabinol (THC), found in cannabis could help with equivalent effectiveness in treating acute types of headache such as migraine and also cluster headache when compared to conventional prescription medications such as amitriptyline. The results revealed that the combination drug THC-CBD had improved effects on reducing the count of cluster headache attacks and their severity.

Request Brochure of Cluster Headache Syndrome Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11360

While there are various triggers of cluster headache studied, such as alcohol, strong smelling substances, extreme exercise or being overheated, and heavy smoking, there could still be room for more research on actual causes. Advancements made in functional neuroimaging are expected to help better understand the condition and find more effective treatments. With this need in consideration coupled with medical advancements, the demand in the global cluster headache syndrome market is anticipated to see a constant rise. Usually, ergotamine, corticosteroids, lithium, methysergide, and verapamil are prescribed as a preventative treatment to patients.

  • Global Cluster Headache Syndrome Market: Vendor Landscape

In order to study the competition prevailing in the market, the report profiles companies such as GlaxoSmithKline plc, ElectroCore Medical LLC, Autonomic Technologies, Inc., and AstraZeneca plc. The recent strategies adopted by these companies to gain a competitive advantage in the market are examined in the report in detail. The report also presents an executive-level blueprint of the strengths and weaknesses of the companies profiled. The threats and opportunities that these companies could face in the near future are also studied in detail.

Leave a Reply

Your email address will not be published. Required fields are marked *